New Avastin projection from CSFB.....
$5.5 billion in US sales in 2008.... wow!!
"Following its successful 2004 launch in colorectal cancer, Avastin appears poised to become the best-selling cancer treatment of all time, besting older standard-bearers Rituxan and Taxol." CSFB projects 2008 U.S. sales for Avastin at approximately $5.5 billion. The firm said U.S. sales of Erbitux, made by ImClone Systems (nasdaq: IMCL - news - people ) and co-marketed with Bristol-Myers Squibb (nyse: BMY - news - people ), will hit a peak of $1.5 billion with growth seen in the head and neck cancer markets, "where competition is limited." CSFB noted that renal cell carcinoma (RCC) is one of the few areas where a drug other than Avastin could dominate and said Pfizer (nyse: PFE - news - people ) drug Sutent "could provide the most compelling single-agent efficacy among RCC biologics."
AI
Market Data 
Markets 
